Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 14 of 14 for “"Kras mutation"”.
-
Signaling crosstalk in cancers
… spectrum of genetic alterations, among which KRAS mutation is the most prominent component with a detection frequency as high as 90%. Hedgehog signaling pathway is involved in developmental process and it’s reactivated in the early stage of carcinogenesis of pancreatic cancer. The coincidence …
-
The Kras/Mapk Pathway and Ligand Independent Activation of Erα: Implications For The Treatment of Endometrial Cancer
… demonstrated that tumors with an activating KRas mutation are resistant to treatment with letrozole even in combination with everolimus. Tumor growth and cellular proliferation were reduced only after the addition of metformin.</p> <p>To assess signaling through ERα, cells with and without an …
-
Prognostic role of tumour associated trypsin inhibitor in colorectal cancer patients
… proteins pSTAT3 and pERK1/2, as well as KRAS mutation status. Apart from a significant association between t-TATI expression and KRAS mutation status, there was no intercorrelation between t-TATI or s-TATI and the investigative markers. Expression of pERK1/2 and pSTAT3, and KRAS mutation …
-
Determination of the Feasibility of Using Cell-Free DNA (cfDNA) in the Q-Clamp KRAS Codon Specific Mutation Test
<p>KRAS is a proto-oncogene which was first identified in Kirsten rat sarcoma virus. The normal KRAS protein performs an essential function in normal tissue signaling and a mutation of a KRAS gene is an essential step in the development of many cancers. Q-Clamp® KRAS codon specific mutation test is …
-
Modelling the effect of loss of function CREBBP mutations in the evolution and treatment of B cell acute lymphoblastic leukaemia (B-ALL)
… thesis I seek to understand the role of CREBBP mutations in the context of B-ALL. These mutations are conserved among different subtypes of B-ALL including hypodiploid (which have a poor prognosis) and have been found in diagnosis and relapse clones. CREBBP mutations tends to coassociate with …
-
Identifying genes that are required for the maintenance of pancreatic ductal adenocarcinoma
… survival rate of less than 5%. Since PDAC is a Kras-driven cancer in that greater than 90% of PDACs contain a Kras mutation, we tested genes that are downstream of Kras. We used RNAi technology to inhibit approximately 30 genes in the canonical Kras effector pathways, Mapk, Pi3k, and Ral. These …
-
Immunohistochemical and molecular studies on ovarian cancer progression and prognosis
… are based on immunohistochemical (IHC) or mutation analyses of tumour samples from a pooled prospective cohort with 154 incident EOC cases from the Malmö Diet and Cancer Study and Malmö Preventive Project. Tissue microarrays (TMAs) were constructed with primary ovarian tumour samples from …
-
The Role of The Epithelial-To-Mesenchymal Transition (Emt) In Lung Cancer Progression
… subset of lung cancer possess an activating KRAS mutation, characterized by a lack of response to chemotherapies with a poor overall 5-year survival rate. Despite the mutational frequency, KRAS remains a challenge to pharmacologically inhibit and current drugs undergoing clinical trials that …
-
Oncogene-induced remodelling of cellular networks
… the mechanisms of pathogenicity of specific mutations are often unclear, severely limiting the efficacy of the therapeutic intervention and disease management. Moreover, we are recognizing that driver mutations once considered sufficient to induce initiation and promotion of cancer are more …
-
A ROLE OF PRL-3 IN AUTOPHAGY AND ITS REGULATION IN HUMAN CANCERS
… ADDITION, I SHOWED THAT CONSTITUTIVELY ACTIVATED MUTATION OF KRAS, WHICH IS ESSENTIAL IN THE DEVELOPMENT OF MANY HUMAN CANCERS, SPECIFICALLY UPREGULATED PRL-3 PROTEIN LEVEL. MY STUDY SHOWED NEW MECHANISMS OF PRL-3 REGULATIONS AS WELL AS THE PATHWAYS AFFECTED BY PRL-3, WHI
-
Identification of novel determinants of primary and acquired resistance to EGFR-targeted therapies in colorectal cancer
… CRC patients that do not exhibit a RAS or BRAF mutation. Despite this, it has been shown that while RAS/BRAFWT patients initially respond to cetuximab treatment, resistance to the EGFR mAb can occur ~3-18 months following initial challenge. With regard to both innate and acquired resistance …
-
Epithelial Memory of Resolved Inflammation Limits Tissue Damage While Promoting Pancreatic Tumorigenesis
… When occurring in the context of pancreatitis, mutations of KRAS accelerate tumor development. We discovered that long after its complete resolution, a transient inflammatory event primes pancreatic epithelial cells to subsequent transformation by oncogenic KRAS. Upon recovery from acute …
-
Associations of sex, anthropometric and reproductive factors with clinicopathological and molecular characteristics of colorectal cancer
… (MSI) status of the tumours was investigated. KRAS/BRAF mutation status was assessed by pyrosequencing. Interestingly, we found that obesity was associated with an increased risk of more advanced CRC, i.e. tumour (T)-stage 3 and 4, lymph node positive and metastatic disease, predominantly in …
-
A cohort study of sex differences and prognostic biomarkers in colorectal cancer
… double-in situ hybridization. In addition, KRAS and BRAF mutational status was assessed by pyrosequencing. Associations with clinicopathological and investigative factors were explored by Chi Square and Spearman’s correlation tests, and Kaplan-Meier analysis and Cox proportional hazards …